

INTRALESIONAL MUMPS, MEASLES AND RUBELLA VACCINE INJECTION FOR THE TREATMENT OF GENITAL WARTS

Thesis

*Submitted for Partial Fulfillment of Master Degree
In Dermatology, Venereology & Andrology*

Presented by

Amira El Sayed Bahgat El Bably
M.B.B.Ch., Ain Shams University

Under Supervision of

Prof. Dr. Hanan Mohamed Ahmed Saleh
*Professor of Dermatology, Venereology & Andrology
Faculty of Medicine, Ain Shams University*

Dr. Ghada Fathy Mohamed

*Assistant Professor of Dermatology, Venereology & Andrology
Faculty of Medicine, Ain Shams University*

Faculty of Medicine
Ain Shams University

2012

حقن لقاح النكاف والحصبة والحميراء داخل الآفة في علاج الثآليل التناسلية

رسالة

توطئة للحصول على درجة الماجستير
في الأمراض الجلدية والتناسلية والذكورة

مقدمة من

الطبيبة / أميرة السيد بهجت البابلي

بكالوريوس الطب والجراحة

جامعة عين شمس

تحت إشراف

الأستاذة الدكتورة / حنان محمد أحمد صالح

أستاذ الأمراض الجلدية والتناسلية والذكورة

كلية الطب - جامعة عين شمس

الدكتورة / غادة فتحي محمد

أستاذ مساعد الأمراض الجلدية والتناسلية والذكورة

كلية الطب - جامعة عين شمس

كلية الطب

جامعة عين شمس

٢٠١٢

SUMMARY

*G*enital warts (Condylomata acuminata, venereal warts, anal warts and anogenital warts) are highly contagious sexually transmitted disease caused by some sub-types of human papillomavirus (HPV). It is spread through direct skin-to-skin contact during oral, genital, or anal sex with an infected partner.

Warts are the most easily recognized symptom of genital HPV infection. They can be caused by strains 6, 11, 30, 42, 43, 44, 45, 51, 52 and 54 of HPV, but types 6 and 11 are responsible for 90% of genital warts cases. It is estimated that 1–2% of the sexually active population between the ages of 15 and 49 is afflicted with these HPV-associated verrucae.

The treatment of warts poses a therapeutic challenge for physicians. No single therapy had been proven effective at achieving complete remission in every patient. As a result, many different approaches to wart therapy exist. These approaches include chemotherapy by (salicylic acid, TCA, podophyllin, podophyllotoxin), cryotherapy mostly by liquid nitrogen, electrosurgery (curettage and cautery), laser therapy and photodynamic therapy. All these previous destructive modalities may be painful, ineffective, costly,

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

وَقُلْ رَبِّ
زِدْنِي عِلْمًا

سورة طه
الآية (١١٤)

صَدَقَ اللَّهُ الْعَظِيمُ



Acknowledgement

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Hanan Mohamed Ahmed Saleh**, Professor of Dermatology, Venereology & Andrology, Faculty of Medicine, Ain Shams University for her keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Prof. Dr. Ghada Fathy Mohamed**, Assistant Professor of Dermatology, Venereology & Andrology, Faculty of Medicine, Ain Shams University, for her kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

I would like to express my hearty thanks to all my family for their support till this work was completed.

Amira El Bably

List of Contents

<i>Title</i>	<i>Page No.</i>
<i>List of Abbreviations.....</i>	<i>I</i>
<i>List of Tables.....</i>	<i>IV</i>
<i>List of Figures.....</i>	<i>V</i>
<i>Introduction</i>	<i>1</i>
<i>Aim of the Work</i>	<i>4</i>
<i>Review of Literature</i>	
▪ <i>Genital Warts</i>	<i>5</i>
▪ <i>Human Papillomavirus (HPV)</i>	<i>11</i>
▪ <i>Human Papillomavirus and Immunology</i>	<i>26</i>
▪ <i>Treatment of Genital Warts.....</i>	<i>41</i>
▪ <i>Immunotherapy</i>	<i>63</i>
<i>Patients and Methods</i>	<i>71</i>
<i>Results</i>	<i>77</i>
<i>Illustrative Cases</i>	<i>93</i>
<i>Discussion</i>	<i>98</i>
<i>Conclusion</i>	<i>104</i>
<i>Recommendations.....</i>	<i>105</i>
<i>Summary</i>	<i>106</i>
<i>References</i>	<i>109</i>
<i>Arabic Summary</i>	

List of Abbreviations

ALA	: Amino-laevulinic acid
APCs	: Antigen Presenting Cells
BCA	: Bichloroacetic acid
BCG	: Bacille Calmette Guerin
BLT	: Buschke-Lowenstein tumor
CD	: Cluster of differentiation
CDC	: Centers for Disease Control and Prevention
CIN	: Cervical intraepithelial neoplasia
COX-2	: Cyclo-oxygenase 2
CPG	: Cytosine phosphate- guanosine
CTL	: Cytotoxic T lymphocytes
DCs	: Dendritic Cells
DNA	: Deoxyribonucleic acid
E	: Early region
EGW	: External Genital wart
FDA	: Food and Drug Administrations
FISH	: Filter in situ hybridization
G	: Gap
G-CSF	: Granulocyte colony- stimulating factor
HIV	: Human immunodeficiency virus
HLA	: Human Leukocyte Antigen
HLA-DP	: Human Leukocyte Antigen- heterodimer protein/peptide antigen receptor
HLA-DQ	: Human Leukocyte Antigen- heterodimer of the MHC class II type

List of Abbreviations (Cont.)

HLA-DR	: Human Leukocyte Antigen- heterodimer cell surface receptor
HPV	: Human Papillomavirus
IL	: Interleukin
INF	: Interferon
IP 10	: Induced Protein 10
ISH	: Tissue in situ hybridization
Kb	: Kilo bases
L	: Late region
LCR	: Long Control region
LCs	: Langerhans Cells
LEEP	: Loop electrosurgical excision procedure
LN	: Lymph Node
LN2	: Liquid Nitrogen
MEM	: Minimal Essential Medium
MHC	: Major Histocompatibility Complex
MMR	: Measles, Mumps and rubella
mRNA	: Messenger Ribonucleic acid
Mw	: killed Mycobacterium w vaccine
NK	: Natural Killer
P 53	: Protein 53
Pap	: Papanicolaou
PCR	: Polymerase Chain Reaction
PMNs	: Polymorphonuclear leukocytes

List of Abbreviations (Cont.)

PPD	: Purified Protein derivative
PV	: Per Vaginam
RRP	: Recurent Respiratory Papillomatosis
S phase	: Synthesis phase
SIL	: Squamous intraepithelial lesions
STDs	: Sexually transmitted diseases
STH	: Southern transfer hybridization
STI	: Sexually transmitted infection
TCA	: Trichloroacetic acid
TGF	: Transforming Growth Factor
Th 2	: T helper 2
Th1	: T helper 1
TNF	: Tumor Necrosis Factor
VLPs	: Viral-like particles
WI-38	: Wistar Institute 38

List of Tables

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
Table (1):	Prevalence of HPV among women with normal cytology in Egypt, Northern Africa and Worldwide	12
Table (2):	Classification of HPV types according to the risks of malignancy	17
Table (3):	CDC Recommendations for Wart Treatment in Specific Anatomic Areas.....	44
Table (4):	Types of Immunomodulators	64
Table (5):	Clinical and demographic data in MMR group.....	79
Table (6):	Clinical and demographic data in control group.....	83
Table (7):	Comparison between MMR and Control group according to the outcome.....	84
Table (8):	Comparison between responders and non responders regarded the sex.	85
Table (9):	Comparison between responders and non responders regarding the number of lesions.....	86
Table (10):	Comparison between responders and non responders regarded the age.....	87
Table (11):	Comparison between responders and non responders regarded the duration of lesions.....	89
Table (12):	Multiple regression analysis for dependent variable response by ANOVA.	91

List of Figures

<i>Fig. No.</i>	<i>Title</i>	<i>Page No.</i>
Fig. (1):	Histopathological picture of Condyloma accuminatum	9
Fig. (2):	Schematic representation of the HPV genome	20
Fig. (3):	Schematic representation of HPV entering a human vagina.....	22
Fig. (4):	Life cycle of HPV	28
Fig. (5):	Simplified summary of immunological response to HPV infection	29
Fig. (6):	Cytopathic effects of HPV infection (koilocytotic atypia).....	57
Fig. (7):	Histology of CIN with cytopathic effects of HPV infection (koilocytosis)	57
Fig. (8):	Graph for responders and non responders regarded the age showing a statistically significant difference.	88
Fig. (9):	Graph for responders and non responders regarded the duration of lesions showing a statistically significant difference.....	90
Fig. (10):	(a) showing genital warts on labia majora before treatment. (b) showing complete clearance of warts after 10 weeks of therapy.....	93
Fig. (11):	(a) showing genital warts on the ventral surface of the penis before treatment. (b) showing complete clearance after 10 weeks of therapy.	93

List of Figures (cont...)

<i>Fig. No.</i>	<i>Title</i>	<i>Page No.</i>
Fig. (12):	(a) showing genital warts on labia majora before treatment. (b) showing complete clearance after 10 weeks of therapy.....	94
Fig. (13):	(a) showing genital warts on labia majora before treatment. (b) showing complete clearance after 10 weeks of therapy.....	94
Fig. (14):	(a) showing genital warts on labia majora before treatment. (b) showing complete clearance after 10 weeks of therapy.....	95
Fig. (15):	(a) showing genital wart on labia majora before treatment. (b) showing partial clearance of the wart after 10 weeks of therapy.....	95
Fig. (16):	(a) showing perianal warts before treatment (b) showing minimal clearance of the warts after 10 weeks of therapy.	96
Fig. (17):	(a) showing genital warts on perineum before treatment. (b) showing minimal clearance of the warts after 10 weeks of therapy.....	96
Fig. (18):	(a) showing a genital wart on labia majora before treatment. (b) showing minimal clearance of the wart after 10 weeks of therapy.....	97
Fig. (19):	(a) showing a genital wart on the dorsal surface of the penis before treatment. (b) showing no improvement of the wart after 10 weeks of therapy.....	97

INTRODUCTION

Human Papilloma Virus (HPV) is a double-stranded DNA virus that causes cutaneous viral warts, most commonly located on the skin and genitalia (*Rivera and Tyring, 2004*). Over 118 types of papillomavirus have been identified, more than 35 types infect the genital tract (*De Villiers and Fauquet, 2004*).

Types 6 and 11 Human Papilloma Virus (HPV) are associated with low risk anogenital warts, and types 16, 18, 31, 33, 45 and 59 are most commonly associated with squamous cell and adenocarcinomas of the cervix (*Brotzman, 2005*). Individuals are likely to be infected by multiple types (*Vandepapeliere et al., 2005*).

Warts of the genital tract carry a much more pernicious threat for women in particular. It has been estimated that up to 70% of sexually active women become infected during their lifetime with human papillomavirus (HPV) (*Baseman and Koutsky, 2005*).

Anogenital warts (venereal or condylomata acuminata) occur in the perineum and on the genitalia or in the genital tract and are considered as one of the most common sexually transmitted diseases. They can be an indication of sexual abuse in children under the age of 3, but may be

transmitted to the neonates of infected women (*Rintala et al., 2005*).

Approximately 23% of warts regress spontaneously within 2 months, 30% within 3 months and 65% to 78% within 2 years (*Sterling et al., 2001*). Previously infected patients have a higher risk for development of new warts than those never infected (*Allen and Siegfried, 1998*). The rate of clearance is influenced by factors such as viral type, host immune status, extent and duration of warts (*Clifton et al., 2003*).

Although there are many destructive and immunotherapeutic options available for the treatment of viral warts, no single treatment has yet proven 100% effective (*Lipke, 2006*). Anogenital warts should receive special consideration and warrant vigilance for other sexually transmitted disease (*Sterling, 2001*).

Destructive therapies include either topical agents, such as salicylic acid, podophyllotoxin, trichloroacetic acid, formaldehyde, 5-fluorouracil and photodynamic therapy, or surgical methods such as cryosurgery, laser ablation, electrocautery, and surgical excision. Immunotherapeutic agents include contact sensitizers, imiquimod, intralesional interferons and oral drugs, such as levamisole, cimetidine, and zinc sulphate (*Dasher et al., 2009*).

Many observations have suggested that wart proliferation is controlled by the immune system, particularly the cell-mediated immunity (*Gonc and Donadi, 2004*). Recently, intralesional immunotherapy by different antigens has been proved effective in the treatment of different types of warts (*Gupta et al., 2008*).

Intralesional immunotherapy employs the ability of the immune system to recognize certain viral, bacterial and fungal antigens that induce a delayed-type hypersensitivity reaction, not only to the antigen but also against the wart virus, which in turn, increases the ability of the immune system to recognize and clear HPV (*Maronn et al., 2008*).

Taking the advantage of the vaccination schedule in our country including mumps, measles and rubella (MMR) vaccine, we designed the present study to evaluate the efficacy and safety of this vaccine in the treatment of genital warts.